Comparative Pharmacology
Head-to-head clinical analysis: CHROMITOPE SODIUM versus SETHOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHROMITOPE SODIUM versus SETHOTOPE.
CHROMITOPE SODIUM vs SETHOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chromitope sodium (sodium chromate Cr-51) is a radioactive diagnostic agent. Chromium-51 is incorporated into red blood cells by binding to hemoglobin. Following intravenous injection, the labeled RBCs distribute within the vascular compartment. The radioactive decay allows measurement of RBC mass and survival via scintillation counting. No pharmacological effect; acts solely as a tracer.
SETHOTOPE is a radiolabeled monoclonal antibody that binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells, delivering beta radiation (177Lu) to cause DNA damage and cell death.
Adult: 1-5 mCi (37-185 MBq) intravenously as a single dose for renal imaging. Dose depends on scan type and patient weight.
1.0 mg IV every 12 hours for 7 days.
None Documented
None Documented
Terminal half-life 70-90 minutes (prolonged in renal impairment to >12 hours).
Terminal elimination half-life: 12 hours (range 10-14 h); clinically, dosing interval is 12-24 h to maintain therapeutic levels
Primarily renal (50-70% as unchanged drug over 24 hours); minor biliary/fecal (10-20%).
Renal: 70% as unchanged drug; fecal: 25% as metabolites; biliary: 5%
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical